Key result
Factor Xa inhibitors reduced the risk of venous thromboembolism recurrence compared to low-molecular-weight heparin and vitamin K antagonists in cancer patients.
Why the study?
An earlier review reported no differences between factor Xa inhibitors and standard anticoagulation, prompting an updated assessment of factor Xa inhibitors for VTE management specifically in cancer patients as more RCTs became available.
Do factor Xa inhibitors reduce recurrent VTE and major bleeding in patients with cancer compared to standard anticoagulation?
Meta-Analysis (n=7,965)
Do factor Xa inhibitors reduce recurrent VTE and major bleeding in patients with cancer compared to standard anticoagulation?
Factor Xa inhibitors are more effective than LMWH and VKA in preventing VTE recurrence in cancer patients, though they may carry a higher risk of major bleeding compared to LMWH.
Answers are grounded in this paper and cite their sources.
Factor Xa inhibitors reduce VTE recurrence versus LMWH or VKA in cancer; confirms superiority for secondary prevention and supports guideline preference.
<ns3:p> <ns3:bold>Background:</ns3:bold> An earlier systematic review reported no differences in the incidence of recurrent venous thromboembolism and major bleeding between factor Xa inhibitors and standard anticoagulation. </ns3:p> <ns3:p>The present meta-analysis aimed to assess the effectiveness of factor Xa inhibitors for the management of venous thromboembolism (VTE), specifically in patients with cancer, as there were more randomized clinical trials (RCTs) available.</ns3:p> <ns3:p> <ns3:bold>Methods:</ns3:bold> The PubMed and Cochrane Library databases were systematically screened for all RCTs assessing factor Xa inhibitor efficacy for VTE management in cancer patients. Using RevMan 5.3, we performed a Mantel–Haenszel fixed-effects meta-analysis of the following outcomes: recurrent VTE, VTE events, and major bleeding rates. </ns3:p> <ns3:p> <ns3:bold>Results:</ns3:bold> We identified 11 studies involving 7,965 patients. Factor Xa inhibitors were superior in preventing VTE recurrence, compared to low-molecular-weight heparin (LMWH) (OR 0.60; 95% CI 0.45–0.80; P < 0.01) and vitamin K antagonists (VKA) (OR 0.51; 95% CI 0.33–0.78; P < 0.01). As prophylaxis, factor Xa inhibitors had a similar rate of VTE compared to VKAs (OR 1.08 [95% CI 0.31–3.77]; P = 0.90) and a lower rate compared to placebo (OR 0.54 [95% CI 0.35–0.81]; P < 0.01). Major bleeding rates were higher with factor Xa inhibitors than with LMWHs (OR 1.34 [95% CI 0.83–2.18]; P = 0.23), but significantly lower than VKAs (OR 0.71 [95% CI 0.55–0.92]; P < 0.01). </ns3:p> <ns3:p> <ns3:bold>Conclusions:</ns3:bold> Factor Xa inhibitors are effective for VTE management in patients with cancer; however, they are also associated with an increased bleeding risk compared to LMWH, but decreased when compared to VKA. </ns3:p>
No takes yet. Share an insight, caveat, or question.
Nugroho et al. (2021) conducted a meta-analysis in Venous thromboembolism in cancer patients (n=7,965). Factor Xa inhibitors vs. Low-molecular-weight heparin (LMWH), Vitamin K antagonists (VKA), or placebo was evaluated on Recurrent VTE (compared to LMWH) (OR 0.60, 95% CI 0.45-0.80, p=<0.01). Factor Xa inhibitors reduced the risk of venous thromboembolism recurrence compared to low-molecular-weight heparin and vitamin K antagonists in cancer patients.
Synapse has enriched 10 related papers. Consider them for comparative context: